Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
54.50 GBX | 0.00% |
|
0.00% | -25.85% |
Feb. 03 | Arecor Therapeutics confident for the future as revenue rises | AN |
Feb. 03 | Arecor Therapeutics Says Non-Clinical PK Data For Oral GLP-1 On Track To Be Delivered In H1'25 | RE |
Business description: Arecor Therapeutics plc
Number of employees: 50
Sales by Activity: Arecor Therapeutics plc
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Biotechnology | 748K | 1.7M | 1.16M | 2.4M | 4.57M |
Geographical breakdown of sales: Arecor Therapeutics plc
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
UK | 44.9K | - | 71K | 1.14M | 2.89M |
USA | - | - | 940K | 784K | 556K |
Switzerland | - | - | - | 240K | 488K |
Germany | - | - | - | - | 332K |
Italy | - | - | - | - | 274K |
India | - | - | - | 135K | 30K |
Rest of World | 380K | 962K | 71K | - | - |
Rest of Europe | 322K | 736K | 76K | 108K | - |
Executive Committee: Arecor Therapeutics plc
Manager | Title | Age | Since |
---|---|---|---|
Sarah Howell
CEO | Chief Executive Officer | 50 | 2021-04-12 |
David J. Ellam
DFI | Director of Finance/CFO | - | 2024-11-17 |
Jan Jezek
CTO | Chief Tech/Sci/R&D Officer | - | 2007-07-31 |
Manjit Rahelu
PRN | Corporate Officer/Principal | - | 2023-04-04 |
David Gerring
PRN | Corporate Officer/Principal | - | - |
Composition of the Board of Directors: Arecor Therapeutics plc
Director | Title | Age | Since |
---|---|---|---|
Alan Smith
BRD | Director/Board Member | 79 | 2021-04-12 |
Sarah Howell
BRD | Director/Board Member | 50 | 2021-04-12 |
Mohammad Fazeli
BRD | Director/Board Member | 60 | 2017-08-31 |
Andrew Richards
CHM | Chairman | 65 | 2021-04-12 |
Christine Soden
BRD | Director/Board Member | 67 | 2021-04-30 |
Jeremy Morgan
BRD | Director/Board Member | 62 | - |
Company details: Arecor Therapeutics plc
Arecor Therapeutics Plc
Chesterford Research Park
CB10 1XL, Little Chesterford
+44 1223 426 060
http://arecor.com
Other Biotechnology & Medical Research
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
0.00% | 0.00% | -65.18% | -85.47% | 25.96M | ||
+1.07% | -0.33% | +30.09% | -0.20% | 48.26B | ||
-1.33% | -6.54% | -18.93% | -14.54% | 34.06B | ||
-0.45% | -1.71% | -0.38% | +22.57% | 26.71B | ||
+0.04% | +7.22% | +72.58% | +85.37% | 16.54B | ||
+1.95% | -2.43% | -35.57% | -19.02% | 15.37B | ||
+6.79% | +30.84% | - | - | 14.08B | ||
+3.35% | +3.51% | -62.67% | -77.46% | 12.7B | ||
-1.24% | -5.69% | -7.92% | -33.76% | 10.42B | ||
-0.65% | -4.04% | -13.14% | +139.12% | 10.36B | ||
Average | +0.95% | +1.09% | -11.23% | +1.85% | 18.85B | |
Weighted average by Cap. | +0.76% | +0.28% | +2.49% | +7.58% |
Sector

Annual profits - Rate of surprise
- Stock Market
- Equities
- AREC Stock
- Company Arecor Therapeutics plc